208 related articles for article (PubMed ID: 32830463)
1. Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Soto E; Banfield C; Gupta P; Peterson MC
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):553-560. PubMed ID: 32830463
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
4. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
6. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
7. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
8. Abrocitinib: First Approval.
Deeks ED; Duggan S
Drugs; 2021 Dec; 81(18):2149-2157. PubMed ID: 34807428
[TBL] [Abstract][Full Text] [Related]
9. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
10. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Kim BS; Silverberg JI; Ständer S; Yosipovitch G; Simpson EL; DiBonaventura M; Kerkmann U; Farooqui SA; Biswas P; Valdez H; Cameron MC
Dermatitis; 2021 Oct; 32(1S):S39-S44. PubMed ID: 34175862
[TBL] [Abstract][Full Text] [Related]
11. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Nezamololama N; Crowley EL; Gooderham MJ; Papp K
Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
[TBL] [Abstract][Full Text] [Related]
12. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
14. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.
Napolitano M; Fabbrocini G; Ruggiero A; Marino V; Nocerino M; Patruno C
Drug Des Devel Ther; 2021; 15():1135-1147. PubMed ID: 33731985
[TBL] [Abstract][Full Text] [Related]
16. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Guttman-Yassky E; Facheris P; Gomez-Arias PJ; Del Duca E; Da Rosa JC; Weidinger S; Bissonnette R; Armstrong AW; Seneschal J; Eyerich K; Estrada YD; Bose SN; Xu D; Chen A; Tatulych S; Güler E; Chan G; Page KM; Kerkmann U
Allergy; 2024 May; 79(5):1258-1270. PubMed ID: 38108208
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
Simpson EL; Wollenberg A; Bissonnette R; Silverberg JI; Papacharalambous J; Zhu L; Zhang W; Beebe JS; Vincent M; Peeva E; Bushmakin AG; Cappelleri JC; Chen L; Sikirica V; Xenakis J
Dermatitis; 2021 Oct; 32(1S):S53-S61. PubMed ID: 33795561
[TBL] [Abstract][Full Text] [Related]
18. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Schmieder GJ; Draelos ZD; Pariser DM; Banfield C; Cox L; Hodge M; Kieras E; Parsons-Rich D; Menon S; Salganik M; Page K; Peeva E
Br J Dermatol; 2018 Jul; 179(1):54-62. PubMed ID: 28949012
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Br J Clin Pharmacol; 2022 Aug; 88(8):3856-3871. PubMed ID: 35342978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]